Clinical Trials · NCT03439709

Multicenter Evaluation of the Effect of Upfront Radiosurgery on Residual Growth Hormone-secreting Pituitary Adenoma

UnknownPhase 3Lanreotide (Unclear)
Phase
Phase 3
Recruitment status
Unknown
Sponsor
Samsung Medical Center
Enrollment
90
Start date
Mar 2018
Locations
1 site, South Korea
Primary endpoint
endocrinologic remission
View Lanreotide compound reference